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with type 2 diabetes: a cross-sectional
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Abstract
Background: In this cross-sectional study, we assessed the possible association of vitamin D deficiency with
self-reported treatment satisfaction and health-related quality of life in patients with type 2 diabetes.
Methods: We performed a sub-analysis of a previous study and included a total of 292 type 2 diabetic patients.
We evaluated treatment satisfaction and health-related quality of life through specific tools: the Diabetes Treatment
Satisfaction Questionnaire and the Audit of Diabetes-Dependent Quality of Life. Vitamin D deficiency was defined as 25
(OH) D serum levels < 15 ng/mL.
Results: Multivariable linear regression models were used to estimate the relationship of vitamin D deficiency with
both outcomes once adjusted for self-reported patient characteristics. Vitamin D deficiency was significantly associated
with the final score of the Diabetes Treatment Satisfaction Questionnaire and the single “diabetes-specific quality of
life” dimension of the Audit of Diabetes-Dependent Quality of Life (p = 0.0198 and p = 0.0070, respectively). However,
lower concentrations of 25-OH vitamin D were not associated with the overall quality of life score or the perceived
frequency of hyperglycaemia and hypoglycaemia.
Conclusions: Our study shows the association between vitamin D deficiency and both the self-reported diabetes
treatment satisfaction and the diabetes-specific quality of life in patients with type 2 diabetes.
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Background
Type 2 diabetes mellitus (T2DM) has a negative impact
on the quality of life of the people who suffer from it.
T2DM involves the physical and emotional overload of a
disease that “has no cure”, that requires life-long treat-
ment and that has therapeutic measures that include the
introduction of lifestyle changes and pharmacological
treatment, often with multiple drugs [1]. The preserva-
tion of health-related quality of life (HRQoL) and the
optimisation of satisfaction with the treatment adminis-
tered stand as two important objectives for the patient
with T2DM [2, 3].
Although traditionally vitamin D has been associated
with calcium-phosphate metabolism, recent epidemiological
studies show the relation between hypovitaminosis D and
several different diseases or conditions, such as diabetes,
cancer, autoimmune disorders, and infectious, respiratory,
or cardiovascular diseases [4]. This diverse physio-
logical burden can be expected as there are vitamin D
receptors in different tissues and the activation of these
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receptors not only induces the modification of the ex-
pression of those genes involved in mineral homeostasis
and bone remodelling but also induces the expression
of more than 200 genes involved in different cellular
pathways that affect mechanisms such as immunomodula-
tion, the control of hormone secretion, inhibition of cell
growth, and induction of cell differentiation. With respect
to diabetes, vitamin D is involved in the secretion and
action of insulin and may influence chronic low-grade
inflammation and angiogenesis [5, 6]. There is an asso-
ciation of vitamin D insufficiency and increased fat in-
filtration in skeletal muscle, independently of body
mass, that might contribute to a decreased insulin ac-
tion [7]. In addition, there is increasing evidence of the
possible role that severe vitamin D deficiency plays as a
modifiable risk factor for mortality, specifically of both
all-cause and cardiovascular mortality in patients with
T2DM, and of its association with the presence and se-
verity of multiple comorbidities [8–10].
Recently, the possible impact of vitamin D deficiency
on HRQoL and other aspects that are of great importance
for the patient (biophysiological, emotional and social
considerations) have been studied in subjects with various
conditions (osteoarthritis, osteoporosis, inflammatory bowel
disease and chronic kidney disease) and in healthy popula-
tions [11–19]. Nevertheless, there are still very few studies
that have analysed the impact of vitamin D deficiency on
the HRQoL of these patients and none of these studies
has assessed its effects on the satisfaction with treatment
[16–20]. Concerning diabetes, a recent cross-sectional
study in non-vitamin D deficient Dutch subjects, with fair
metabolic control of their T2DM, found no association
between vitamin D levels and HRQoL [21]. Similarly, in a
randomised, double-blind, placebo-controlled trial, the
same researchers showed that there was no effect of vita-
min D supplementation (50,000 IU for six months) on
self-reported HRQoL, which was assessed using the Short
Form 36 Health Survey, in patients with similar character-
istics [22]. Meanwhile, Mager et al. analysed the impact of
six months of different doses of vitamin D3 supplementa-
tion (2000 IU/daily or 40,000 IU/monthly), administered
to Canadian adults with diabetes mellitus (more than 95%
with T2DM) and other chronic diseases, on the following
primary outcomes: vitamin D status, bone health and
Fibroblast Growth Factor-23, and on the following sec-
ondary outcome: HRQoL. The results of this open-label
randomised clinical trial did not show any significant im-
provement in bone mineral density or HRQoL [23]. It
must be noted that all the studies on diabetes that are
mentioned above excluded subjects with vitamin D defi-
ciency. In contrast, the results of a recent sub-analysis of the
Comprehensive Dialysis Study, with a well-characterised
cohort of incident dialysis patients (60.4% with diabetes),
did find an association between 25-OH vitamin D
deficiency (< 15 ng/ml) and poorer self-reported mental
health and physical activity [10]. Thereby, the status of
vitamin D is related to unfavourable outcomes of dis-
ease and complications that affect the quality of life of
patients. In the current study, we hypothesised that, in
patients with T2DM, vitamin D deficiency is associated
with lower levels of satisfaction with their treatment
and poorer HRQoL.
Methods
Study design, participants and study procedures
The current study is the result of a sub-analysis of a pre-
vious cross-sectional study conducted by our research
group. The primary objective of the current study was to
evaluate the impact of retinopathy on the quality of life
and treatment satisfaction in patients with T2DM with-
out any other advanced complications of diabetes [2].
From a total sample of 297 participants, aged 40–75 years,
we included a final number of 292 subjects. Five subjects
were excluded from the initial study because they were re-
ceiving vitamin D supplementation during the six months
prior to recruitment. Concentrations of 25-OH vitamin D
were measured using a chemiluminescent microparticle
immunoassay in an Architect i2000SR analyser (Abbott
Diagnostics, Lake Forest, IL, USA), with an intra-assay
and inter-assay variability of 2.3% and 6.2%, respectively.
Vitamin D deficiency was defined based on the cut-off
point of serum vitamin D concentrations below 15 ng/mL
(37.4 nmol/L). This cut-off concentration was found to
define the vitamin D deficiency threshold below which
there was a higher frequency of diabetic retinopathy in the
subjects of a previous study [9]. Additionally, all three pre-
vious studies addressing the issue of the association of
vitamin D and quality of life in diabetic patients used this
concentration as the limit to define vitamin D deficiency
[21–23]. A patient was classified as having dyslipidaemia
and hypertension when she/he received medication for
these conditions. The characteristics of the study popu-
lation and the detailed procedures of the study were de-
scribed and reported in detail in a previous publication
[2]. The study was approved by the Ethics Committee
of our institution in accordance with the Declaration of
Helsinki. All study participants provided signed informed
consent.
Patient-reported outcomes
To assess HRQoL, we used the latest version of the
specific quality of life questionnaire for diabetic pa-
tients, the Audit of Diabetes-Dependent Quality of Life
(ADDQoL-19), which is designed to assess the patient’s
personal perspective on the impact of diabetes and its
treatment on quality of life [24]. The first two items are
general and scored separately: the first measures current
quality of life, from − 3 (extremely bad) to + 3 (excellent),
Alcubierre et al. Health and Quality of Life Outcomes  (2018) 16:44 Page 2 of 8
while the second evaluates the overall impact of diabetes
on quality of life, from − 3 (maximum negative impact of
diabetes) to + 1 (maximum positive impact of diabetes).
The individual items consist of questions on 19 specific di-
mensions of life (such as social and affective life). The
ADDQoL allowed us to calculate a final weighted score,
the average weighted impact, which ranged from − 9
(maximum negative impact of diabetes) to + 3 (maximum
positive impact of diabetes) and weighted the effects of
diabetes and its treatment on the quality of life of the par-
ticipants [24]. The ADDQoL has previously been validated
in our country in patients with T2DM [25, 26].
Similarly, to measure the patient’s satisfaction with
her/his treatment, we chose the Diabetes Treatment Sat-
isfaction Questionnaire–status version (DTSQ-s), which
is designed to assess the degree of satisfaction of diabetic
patients with the treatment they receive [27]. This instru-
ment has also been validated for the Spanish population
[28]. It consists of eight questions, two of which are scored
separately (perception of the frequency of hyperglycaemia
and hypoglycaemia). All the items have seven possible an-
swers, ranging from 0 to 6. The degree of overall satisfac-
tion (final score) is expressed by a global score of 0 to 36,
with higher values expressing greater degrees of satisfac-
tion with treatment [27]. The use of the DTSQ-s has been
widely recommended by the World Health Organisation
and by the International Diabetes Federation as a valid
instrument that allows for the accurate measurement of
patient satisfaction with their treatment in patients with
types 1 or 2 diabetes [29].
Statistical analysis
Non-normally distributed quantitative variables were de-
scribed by median values (interquartile range) and were
compared between vitamin D deficiency groups using
the Mann-Whitney test. Normally distributed quantitative
variables were described by mean values (standard devi-
ation) and were compared between both groups using the
Student’s t-test. Qualitative variables were summarised as
frequencies (percentages) and were compared using the
chi-squared test. The statistical analysis included the esti-
mation of univariate and multivariable linear regression
models for the variability of the overall mean score of
quality of life and the single item assessments of “present
quality of life” and “diabetes-specific quality of life” pro-
vided by the ADDQoL. The treatment satisfaction score
and the hyperglycaemia and hypoglycaemia frequencies
were also fitted to univariate and multivariable linear re-
gression models to assess their relationship with vitamin
D before and after adjusting by significantly related patient
characteristics. We assessed the significant contribution
(by likelihood ratio test) or confounding effect (detected
by changes in coefficients over a 15%) for all the pa-
tients’ characteristics collected and reported in Table 1.
Interactions found in the previous study were included
in the models [2]. A robust quantile regression for the
median score was performed in case of deviations from
the linear model assumption of normally distributed re-
siduals as assessed by normal probability plot. The esti-
mated post-host statistical power was 100% and 99.8%
for models of diabetes-specific quality of life and Dia-
betes Treatment Satisfaction Questionnaire score, given
their coefficients of determination. A significance level
of 0.05 and the statistical software R were used.
Results
Table 1 summarises the ADDQoL-19 and DTSQ-s results,
clinical and socio-demographic characteristics, and their
comparisons between the two study groups. Vitamin D
concentrations were 22.7 [18.7; 28.0] ng/mL in patients
without deficiency and 11.1 [9.18; 13.2] ng/mL in patients
with vitamin D deficiency.
Unadjusted analysis in Table 2 shows that when vita-
min D was used as an explanatory variable, the diabetes-
specific quality of life score was significantly associated
with a proportional increase in vitamin D concentration.
However, when we used two groups of vitamin D levels
(deficiency, < 15 ng/mL vs. non-deficiency > 15 ng/mL),
the coefficients showed the differences between the
means of both groups. These analysis, showed stronger
associations of the study variables with vitamin D defi-
ciency (< 15 ng/mL) than with serum vitamin D concen-
trations as a continuous variable. Vitamin D deficiency
was significantly associated with lower quality of life ac-
cording to all the measures of ADDQoL (average score
(p = 0.020), present quality of life (p = 0.040) and dia-
betes-specific quality of life (p = 0.001), as well as with
lower satisfaction with diabetes treatment (p = 0.004). The
perception of hyperglycaemia or hypoglycaemia frequency
did not show any significant association with vitamin D
deficiency (p = 0.240 and p = 0.890, respectively).
As reported in our previous study [2], the multivari-
able analysis showed a second-order interaction between
diabetes duration, the presence of diabetic retinopathy,
and insulin therapy (p = 0.003). Diabetes-specific quality
of life was significantly associated with three factors that
interacted with each other: diabetes duration, treatment
with insulin, and the presence or absence of diabetic ret-
inopathy. Additionally, it was the only ADDQoL out-
come keeping the significant association with vitamin D
deficiency, showing a lower diabetic-specific quality of
life in the multivariable regression model (p = 0.007)
(Table 3).
Vitamin D deficiency was also significantly associated
with a lower overall treatment satisfaction as assessed by
the DTSQ (p = 0.020). As in the prior model [2], diabetic
retinopathy had lower treatment satisfaction in relation
to the duration of diabetes (p = 0.014) Moreover, former
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smokers had lower satisfaction compared with the group
of non-smokers (p = 0.043). However, physically active
patients had greater treatment satisfaction (p = 0.003)
(Table 4).
Sensitivity analysis
Since some deviations from the normal distribution were
observed in both multivariable linear models for extreme
score values, and linear regression is highly influenced
by them, the same models were fitted for the median
scores by using quantile regression model, which is the ro-
bust alternative to linear regression to predict the median
difference instead of the mean. The estimated adjusted
coefficient to vitamin D deficiency (levels < 15 ng/dL)
was − 0.491 in diabetes-specific quality of life, with a
95%CI of − 0.971 and − 0.166, showing also a significant
reduction, even more significant than the one estimated
of − 0.283 by applying multivariable linear regression.
For diabetes treatment satisfaction score, the estimated
adjusted coefficient of vitamin D deficiency was − 1.76,
Table 1 Demographic and clinical characteristics of the study subjects
All patients(n = 292) No Vitamin D deficiency (n = 192) Vitamin D deficiency (n = 100) p-value
Vitamin D (ng/mL) 18.4 [13.1;25.0] 22.7 [18.7;28.0] 11.1 [9.18;13.2]
Gender (female) 148 (50.7%) 101 (52.6%) 47 (47%) 0.432
Age, years 60.0 [51.8; 68.0] 60.0 [50.8; 68.0] 59.5 [52.8; 67.0] 0.683
Retinopathy 145 (49.7%) 88 (45.8%) 57 (57.0%) 0.091
Education 0.672
Not even primary 38 (13.0%) 22 (11.5%) 16 (16.0%)
Complete primary 165 (56.5%) 111 (57.8%) 54 (54.0%)
Complete secondary 68 (23.3%) 44 (22.9%) 24 (24.0%)
Graduate or higher 21 (7.19%) 15 (7.81%) 6 (6.0%)
Caucasian 281 (96.2%) 189 (98.4%) 92 (92.0%) 0.009
Smoking (Current/Former/Never) 60/93/137 39/62/89 21/31/48 0.961
Diabetes duration (years) 8 [4.0; 15.0] 8 [4.0; 14.0] 10 [5.0; 15.0] 0.322
HbA1c (mmol/mol) 59.6 [51.4; 69.4] 56.8 [48.9; 66.1] 61.7 [51.9; 70.5] 0.049
Hypertension 165 (56.5%) 108 (56.2%) 57 (57.0%) 1.000
Dyslipidaemia 128 (43.8%) 88 (45.8%) 40 (40.0%) 0.407
Antiplatelet agents 114 (38.7%) 70 (36.5%) 43 (43.0%) 0.336
Psychotropic drugs 81 (27.7%) 50 (26.0%) 31 (31.0%) 0.447
Serum creatinine (mg/dl) 0.79 [0.68; 0.93] 0.80 [0.69; 0.92] 0.78 [0.66; 0.94] 0.561
Systolic BP (mmHg) 139 (18.7) 138 (18.3) 142 (19.1) 0.086
Diastolic BP (mmHg) 76.7 (10.7) 76.8 (10.6) 76.5 (11.0) 0.808
Waist (cm) 106 (11.8) 105 (11.0) 107 (13.1) 0.162
Diabetes treatment 0.489
Oral antidiabetic agents 158 (54.1%) 106 (55.2%) 52 (52.0%)
Oral antidiabetic agents + Insulin 74 (25.3%) 45 (23.4%) 29 (29.0%)
Insulin 22 (7.53%) 13 (6.77%) 9 (9.0%)
Diet 38 (13.0%) 28 (14.6%) 10 (10.0%)
Physical activity (> 25 min/day) 113 (38.7%) 68 (35.4%) 45 (45.0%) 0.142
Present quality of life 0.69 (1.15) 0.79 (1.09) 0.50 (1.24) 0.044
Diabetes-specific quality of life −1.0 [−2.0; 0.0] 0.0 [−1.0; 0.0] −1.0 [−2.0; 0.0] 0.001
Average weighted impact: ADDQoL score 0.58 [−1.23; −0.17] −0.53 [− 1.08; − 0.17] 0.74 [− 1.59; − 0.18] 0.091
Perceived hyperglycaemia frequency 3.0 [1.0; 5.0] 3.0 [1.0; 5.0] 4.0 [1.0; 5.0] 0.257
Perceived hypoglycaemia frequency 0.0 [0.0; 2.0] 0.0 [0.0; 2.0] 0.0 [0.0; 2.0] 0.850
Final DTSQ score 27.0 [23.0; 30.0] 28.0 [23.0; 31.0] 25.0 [21.0; 28.2] 0.001
Values are shown as the mean (SD), median [interquartile range] or frequency (%). The p-values correspond to the unadjusted univariate analysis, which compares
the difference for each variable between patients with and without vitamin D deficiency.
HbA1c glycated haemoglobin, ADDQoL Audit of Diabetes-Dependent Quality of Life, DTSQ Diabetes Treatment Satisfaction Questionnaire
Alcubierre et al. Health and Quality of Life Outcomes  (2018) 16:44 Page 4 of 8
with a 95%CI of − 3.24 and − 0.64, showing also a signifi-
cant reduction, very close to the − 1.73 value estimated by
applying multivariable linear regression. Therefore, there
is a significant reduction in both, diabetes-specific quality
of life and diabetes treatment satisfaction associated with
vitamin D deficiency.
Discussion
The results of this study showed an association of vita-
min D deficiency with decreased treatment satisfaction
in patients with T2DM. Concerning HRQoL, although in
global terms the average weighted impact according to
the ADDQoL score was not associated with hypovitami-
nosis D, the results for the specific item that evaluated
diabetes-related quality of life were significantly poorer
in patients with vitamin D deficiency. To our knowledge,
this is the first study that demonstrates the association
of vitamin D deficiency with these important patient-
reported outcomes in patients with type 2 diabetes
mellitus.
The association found in the present study between
vitamin D deficiency and quality of life in patients with
T2DM is consistent with findings in other conditions.
Specifically, in cross-sectional studies, an association has
been reported between vitamin D deficiency (defined as
25 (OH) D < 20 ng/mL) and quality of life, assessed with
specific questionnaires, in elderly Japanese women with
osteoporosis who presented other comorbidities [13]. In
Korean subjects with osteoarthritis, an independent
association was also observed between vitamin D deficiency
(25 (OH) D < 10 ng/mL) and a worse quality of life, as
assessed by the EuroQOL-5 dimension, the EQ-5D index,
and the EuroQOL-visual analogue scale (EQ-VAS) [14]. In
a recent meta-analysis that mainly included intervention
studies (73%), Hoffman et al. confirmed the weak to moder-
ate benefits, in terms of self-reported quality of life, of
vitamin D supplementation used on a short-term basis
Table 2 Unadjusted models of the association of vitamin D with quality of life and treatment satisfaction scores
Vitamin D concentrationa Vitamin D deficiencyb
Coefficient SE p Coefficient SE p
Quality of life variables
Average weighted impact: ADDQoL score 0.005 −0.007 0.430 −0.301 − 0.127 0.020
Present quality of life 0.007 −0.007 0.370 −0.292 −0.141 0.040
Diabetes-specific quality of life 0.016 −0.006 0.006 −0.393 −0.113 0.001
Treatment satisfaction variables
Final score of DTSQ 0.064 −0.040 0.110 −2.212 −0.759 0.004
Perceived hyperglycaemias frequency −0.015 0.014 0.320 0.333 −0.280 0.240
Perceived hypoglycaemias frequency 0.018 −0.012 0.130 0.034 −0.235 0.890
Regression coefficient (together with its standard error and p-value) estimated by simple linear regression models associated to vitamin D (25(OH) D serum
concentrationa, or the presence of vitamin D deficiency defined as levels of 25(OH) D < 15 ng/mL (37.4 nmol/L)b. Dependent variables are each of the three
independent scores from each of the questionnaires, ADDQoL and DTSQ
Table 3 Multivariable linear model for diabetes-specific quality
of life
Coefficient Estimate SE p-value
Intercept −0.214 0.171 0.218
Vitamin D deficiencyb −0.283 0.104 0.007
Diabetes duration (years) −0.041 0.039 0.297
Diabetes duration-squared (years2) 0.002 0.002 0.271
Retinopathy 0.299 0.346 0.389
Insulin 1.409 0.793 0.077
Retinopathya insulin −2.771 0.918 0.003
Diabetes durationa insulin −0.588 0.234 0.013
Diabetes duration-squareda insulin 0.033 0.014 0.022
Diabetes durationa retinopathy −0.112 0.079 0.161
Diabetes duration-squareda retinopathy 0.003 0.004 0.428
Diabetes durationa retinopathya insulin 0.743 0.247 0.003
Diabetes duration-squareda retinopathya
insulin
−0.038 0.015 0.011
Multiple R-squared: 24.97%. adenotes the existence of interactions between
the variables. bVitamin D deficiency is defined as levels of 25(OH) D below
15 ng/mL (37.4 nmol/L)
Table 4 Multivariable linear model for final Diabetes Treatment
Satisfaction Questionnaire score
Coefficient Estimate Standard error p-value
Intercept 25.382 1.039 < 0.001
Vitamin D deficiencyb −1.734 0.740 0.020
Insulin −1.500 0.961 0.119
Physical activity > 25 min 2.173 0.723 0.003
Current smoker 0.548 0.936 0.559
Former smoker −1.628 0.803 0.043
Diabetes duration (years) 0.156 0.091 0.085
Retinopathy 1.954 1.191 0.102
Diabetes durationa retinopathy −0.265 0.107 0.014
Multiple R-squared: 12.78%. adenotes the existence of interactions between
the variables. bVitamin D deficiency is defined as levels of 25(OH) D below
15 ng/mL (37.4 nmol/L)
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(< 6 months) in diseased populations (haemodialysis,
rheumatic disease, heart failure, diffuse musculoskeletal
pain or fatigue, sickle cell disease, chronic pain and
Crohn’s disease) [30].
Concerning previous studies in diabetic patients,
Krul-Poel et al. recently reported the results of a
cross-sectional study that showed the absence of an
association between vitamin D levels and HRQoL in
non-vitamin D deficient Dutch subjects with T2DM
[21]. Similarly, in an intervention study, the same re-
search group could not show any improvements after
six months of vitamin D supplementation (cholecalcif-
erol 50,000 IU/month versus placebo) in patients who
had T2DM with considerable associated comorbidities
(micro- and macrovascular complications) [22]. In an-
other intervention trial, Mager et al. reported that both
daily (2000 IU/D) and monthly (40,000 IU/month) sup-
plementation with vitamin D3 only correlated to a slight
increase in the scores of the health-related quality of
life questionnaire Short Form 36 Health Survey in eld-
erly Canadian participants (95% with T2DM) with long-
term diabetes duration (7–20 years) and chronic kidney
disease [23]. At this point, it is very important to note
that all these studies excluded subjects with vitamin D
deficiency. Therefore, the previous evidence showing
the lack of association of vitamin D or its supplementa-
tion with quality of life did not include subjects with
vitamin D deficiency. Thus, our study is the first to ad-
dress the issue of the association of vitamin D and QoL
in subjects with type 2 diabetes without excluding those
with lower concentrations of vitamin D.
The assessment of HRQoL through generic tools may
also explain, at least partially, the differences reported. It
should be highlighted that previous studies did not meas-
ure HRQoL using questionnaires specifically designed and
validated for patients with diabetes. It is still common in
the literature on chronic diseases to empirically assess
HRQoL through the use of generic instruments [30]. The
results of our research confirmed that, when specific ques-
tionnaires are used to assess quality of life, particularly
those designed for the particular disease under consider-
ation, different results may be obtained.
Despite treatment satisfaction as a subjective outcome
measure in healthcare has been investigated in the past
decades [31], this is the first study that shows a relation-
ship between vitamin D status and treatment satisfaction
in diabetic patients. We believe that it is very relevant to
identify the factors that influence satisfaction with treat-
ment in patients with chronic diseases, especially in dia-
betes. This outcome measure is considered an important
indicator of the quality of healthcare, besides being a re-
liable indicator of adherence to treatment [3].
To the best of our knowledge, this is the first report
of a positive association between vitamin D deficiency
(< 15 ng/mL) and both diabetes-related quality of life
and satisfaction with treatment in patients with T2DM
non-supplemented with vitamin D. Additionally, this is
the first study that used questionnaires that are specific
for diabetes patients. The limitations of the present
study include those that are intrinsic to its design. The
use of a cross-sectional study design does not allow the
establishment of a causal relationship between vitamin
D deficiency and the study outcomes. Regarding the
methodology, we acknowledge that the measurement of
vitamin D concentrations was not done using liquid
chromatography, the gold standard method for determin-
ation of vitamin D. However, we used a method that has
been validated in other clinical studies. Additionally, it is
important to note that this study was not primarily de-
signed to assess the association between vitamin D defi-
ciency and either HRQoL or treatment satisfaction. The
absence of other advanced complications of diabetes in
the participants of this study does not allow the extrapola-
tion of the results to the general T2DM population.
However, the general characteristics of study subjects
are close to the general type 2 diabetes population in
our region [32].
The question of whether vitamin D supplementation
improves HRQoL and/or treatment satisfaction cannot
be addressed with a study like the current one. Addition-
ally, we cannot rule out the potential existence of a reverse
association that may point to the fact that the HRQoL sta-
tus or treatment satisfaction could be associated with be-
haviors that predispose patients to lower vitamin D levels.
Conclusion
The current study showed that in patients with T2DM
vitamin D deficiency is associated with a poorer perception
of diabetes-specific quality of life and less satisfaction with
diabetes treatment. Additionally, this research demon-
strates the need to undertake further prospective and inter-
vention studies to establish the role of the treatment of
vitamin D deficiency in modifying the subjective measures
of health status that are more important for patients with
diabetes (HRQoL and satisfaction with treatment) and to
determine the causal relationship between these variables.
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